FDA gives AstraZeneca the thumbs-up to restart PhIII Covid-19 vaccine trials, and J&J is preparing to resume its study

Max Gelman

Senior Editor

Several countries had restarted their portions of AstraZeneca’s global Phase III Covid-19 vaccine trial after the study was paused worldwide in early September, but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA gives AstraZeneca the thumbs-up to restart PhIII Covid-19 vaccine trials, and J&J is preparing to resume its study

Max Gelman

Senior Editor

Sign up to read this article for free.

Merck’s long-awaited obesity move is an oral GLP-1 from China

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

Tessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger

Novo Nordisk partners with Broad Institute spinout Photys after the startup's layoffs

FDA gives As­traZeneca the thumbs-up to restart PhI­II Covid-19 vac­cine tri­als, and J&J is prepar­ing to re­sume its study

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

FDA gives AstraZeneca the thumbs-up to restart PhIII Covid-19 vaccine trials, and J&J is preparing to resume its study

Merck’s long-awaited obesity move is an oral GLP-1 from China

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

Tessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger

Novo Nordisk partners with Broad Institute spinout Photys after the startup's layoffs